Child growth and neurodevelopment after maternal antenatal antibiotic treatment.
Karoliina Videman, Lotta Hallamaa, Otto Heimonen, Charles Mangani, Mari Luntamo, Kenneth Maleta, Per Ashorn, Ulla Ashorn
Author Information
Karoliina Videman: Faculty of Medicine and Health Technology, Center for Child, Adolescent and Maternal Health Research, Tampere University, Tampere, Finland karoliina.videman@tuni.fi. ORCID
Lotta Hallamaa: Faculty of Medicine and Health Technology, Center for Child, Adolescent and Maternal Health Research, Tampere University, Tampere, Finland.
Otto Heimonen: Faculty of Medicine and Health Technology, Center for Child, Adolescent and Maternal Health Research, Tampere University, Tampere, Finland.
Charles Mangani: Department of Public Health, School of Public Health and Family Medicine, College of Medicine Malawi, Blantyre, Malawi.
Mari Luntamo: Faculty of Medicine and Health Technology, Center for Child, Adolescent and Maternal Health Research, Tampere University, Tampere, Finland.
Kenneth Maleta: Department of Public Health, School of Public Health and Family Medicine, College of Medicine Malawi, Blantyre, Malawi.
Per Ashorn: Faculty of Medicine and Health Technology, Center for Child, Adolescent and Maternal Health Research, Tampere University, Tampere, Finland.
Ulla Ashorn: Faculty of Medicine and Health Technology, Center for Child, Adolescent and Maternal Health Research, Tampere University, Tampere, Finland.
OBJECTIVE: To assess whether intermittent preventive treatment of pregnant women (IPTp) with sulfadoxine-pyrimethamine (SP) and azithromycin (AZI) in a malaria-endemic area leads to sustained gains in linear growth and development in their offspring. DESIGN: Follow-up study of a randomised trial. SETTING: Mangochi District in rural southern Malawi. PARTICIPANTS: 1320 pregnant women and their offspring. INTERVENTIONS: IPTp monthly with SP and twice with AZI (AZI-SP group), monthly with SP but no AZI (monthly SP), or twice with SP (control). No intervention was given to children. MAIN OUTCOME MEASURES: Cognitive performance using Raven's Coloured Progressive Matrices (CPM) at 13 years of age; mean height and height-for-age Z-score (HAZ), cumulative incidence and prevalence of stunting (HAZ <-2); weight, body mass index, mid-upper-arm circumference and head circumference. RESULTS: At approximately 13 years of age, the mean CPM score was 14.3 (SD 3.8, range 6-29, maximum 36), with no differences between groups. Children in the AZI-SP group were on average 0.4 cm (95% CI -0.9 to 1.7, p=0.6) taller than those in the control group. For cumulative incidence of stunting, the HR in the AZI-SP group was 0.72 (95% CI 0.61 to 0.84, p<0.001) compared with the control and 0.76 (95% CI 0.65 to 0.90, p<0.001) compared with the monthly SP groups. There was no intergroup difference in stunting prevalence or anthropometric measurements. CONCLUSIONS: In rural Malawi, maternal intensified infection control during pregnancy reduces offspring's cumulative incidence of ever being stunted by 13 years of age. In this study, there was no evidence of a positive impact on cognitive performance. TRIAL REGISTRATION NUMBER: NCT00131235.
